Cognition Therapeutics Q1 net loss narrows on lower expenses

Cognition Therapeutics

07/05/2026 21:51

Overview

US biopharma firm's Q1 net loss narrowed yr/yr due to lower R&D and admin expenses

Company ended Q1 with $31.2 mln in cash, expects runway through Q2 2027

FDA meeting on zervimesine in DLB psychosis set for May 2026; Alzheimer's trial results expected 2027

Outlook

Company expects FDA meeting in May 2026 to inform registrational plans for zervimesine in DLB psychosis

Topline results from Phase 2 Alzheimer's study anticipated in 2027

Company estimates cash runway sufficient to fund operations through Q2 2027

Result Drivers

LOWER R&D SPEND - Co said decrease in research and development expenses was driven by reduced trial activities and professional fees

LOWER ADMIN COSTS - Co said decrease in general and administrative expenses was due primarily to lower stock compensation, compensation and professional fees

Company press release: ID:nGNXbddJcx

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$4.57 mln
Q1 Income From Operations
-$8.82 mln
Q1 Operating Expenses
$8.82 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cognition Therapeutics Inc is $3.50, about 184.6% above its May 6 closing price of $1.23

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)